Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Phase III TULIP 2 trial of anifrolumab in SLE meets primary endpoint

Aug. 29, 2019

For proinflammatory antibody, too much of a bad thing is a good thing

Aug. 29, 2019

Bristol-Myers Squibb presents discovery of lupus candidate BMS-615

Aug. 28, 2019

FDA grants approval for Taltz as treatment of active ankylosing spondylitis

Aug. 27, 2019

Medshine Discovery identifies Janus kinase inhibitors

Aug. 23, 2019

Identifying the cause of lupus cognitive dysfunction

Aug. 22, 2019

Placental growth factor may be autoimmune disease target

Aug. 22, 2019

PI3K-alpha tested as a therapeutic target for prevention of heterotopic ossification

Aug. 21, 2019

FDA approves Rinvoq for the treatment of moderate to severe rheumatoid arthritis

Aug. 19, 2019

Fast skeletal muscle troponin activators can counter skeletal muscle fatigue

Aug. 16, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...